Tag: PROW

Blue Horseshoe Stocks Kicks Off 2014 With a Bang!

Cannabis Sector Report

Our tenacity in covering one of the hottest stories of 2013 just won’t stop paying dividends, and all signs point to the sustaining of that trend in 2014.

Lately, some of you might have been wondering why we have been so keen to continue our focus on marijuana-related stocks (aside from the percentage gains they’ve already afforded us, collectively numbering in the thousands). You got your definitive answer yesterday, when 2014 trading kicked off, and the plethora of pot stocks we’ve been tracking proceeded to put some serious coin in our pockets!

While some newsletters have yet to even release their first picks of the new year, we are already tallying up a number of winning selections in this sector (and others).

Cannabis Science, Inc. CBIS

We caught CBIS off of its 52-wk lows (.028) in December. Following yesterday’s huge session, we saw a high of .087. That marks a huge 211% gain from our December alerts. Those who may have only caught yesterday’s report, still had the chance at up to 57% from the daily low of .0555.

GreenGrow Technologies, Inc. GRNH

From a low of .045 to a high of .0795, GRNH put up an excellent session to follow our morning mention, giving traders the chance at a very respectable 77% gain. Back on November 18th, we bore witness to a .02-low on GRNH. From that level, yesterday’s high represents a increase of 298%

Hemp, Inc. HEMP

HEMP traded in a daily range from .02-.0318, offering us gains of up to 59% on the day. Like the previously mentioned plays, HEMP appears to want to gap up today. The momentum we’re observing in all of these stocks could take awhile to dry up.

GrowLife PHOT

PHOT didn’t disappoint either, with it’s maiden session of 2014 seeing a low of .157 give way to a high of .2075, a solid move of 32%

Those were just the top gainers of the cannabis stocks we’ve been tracking, several others, including MDBX, ERBB, TRTC, FITX and more, also posted positive gains on the day, and will continue to remain on our watchlists moving forward.

Plug Power, Inc. PLUG 

Shifting gears from the marijuana stocks, we once again have PLUG. Following its appearance in yesterday’s newsletter (where we mentioned that this play had already made a move of over 1800% for us) PLUG would go on to have a bang-up first session of the year, dipping to a low of 1.89 before running up to 2.33, and giving us added gains to the tune of 23% The stock closed at the high of day, and as is always the case when that happens, we are on a sharp lookout for continued momentum. It appears that’s just what we’re going to get, as the stock is already trading up in the 2.50-range this morning on relatively heavy premarket volume.

Extended Watchlist:
PROW, RSOL, OIBR, RIBT, FCEL, NVAX

PROW, NQ, PLUG, Cannabis Stocks & Extended Watchlist

Cannabis Sector Stays Hot
–
It was really hard not to make a profit off of the marijuana stocks featured in Tuesday’s final report of 2013. Nearly every single one closed in the green on significant-to-heavy volume, with some of the more notable gains coming from CBIS (+28%), HEMP (+29%), and FITX (+38%). This surge of investor interest in the sector as a whole comes in step with the first stores selling legal pot for recreational use yesterday in Colorado.

It will be important to keep an eye on the developments out of Colorado and Washington, where legalization has already been voted into law, as they will be acting as a litmus test for the rest of the nation. We know that many state legislatures have already begin to entertain the idea of following in the footsteps of the “green revolution” currently taking place out West. We’ll be certain to stay hot on the trail of this story as it unfolds, because this is an industry that is positioned for a boom; and in truth we have been way ahead of the pack in anticipation of this occurrence. Passing into 2014, our coverage of the sector has spanned three calendar years.

Plug Power, Inc. PLUG 

We’re closing in a full year of coverage on PLUG, with our first ever mention coming last February, and it turned out to be one of our more successful plays from 2013. Our scanners picked up on this stock as it was coming off of its 52-wk low at .1155. Over the course of the spring and into summer, PLUG continued to push ever upward, running past .50 in September and reaching highs in the .70’s in September.

If it had stopped there, we still would have called that quadruple-bagger one of the year’s best alerts, but indeed, the stock has been pressing its way to new, impressive highs. The peak of which was reached in early December when we witnessed trades at 2.2399. For anyone without a calculator on hand, that’s an unbelievable move of 1839%

NQ Mobile, Inc. NQ

NQ first appeared in our reports back on October 29th, and on that day, we saw a low of 8.42. The stock had recently taken a huge spill from the $24-range and we were keen to take advantage of the rebound. It has taken less than three months for that plan to come to fruition, and we are extremely pleased with the results so far. As of the high reached on Tuesday, 16.21, NQ has made an overall move for us on the order of 93%

Progress Watch Corp. PROW

On Tuesday we mentioned that while we had already followed PROW from lows at .0065 to its then-current price of .013, that we were looking for a break of the .013 -mark to put PROW in Blue Sky Breakout mode. We did indeed witness that break once the session ensued, and PROW spiked as high as .0194, giving us the chance at close to 200% in gains so far.

It made a strong close as well, holding roughly 90% of its gains, and ending the session at .019 on more than twice the 3mo. average volume, so continuing activity on PROW could get rather interesting.

Extended Watchlist:
MCP, WPCS, BLDP, ARIA, MDNT(Reader’s pick, coming off recent 52-week lows, thanks John!)

KNDI, PPHM & Extended Watchlist

Kandi Technologies Group, Inc. KNDI

This morning, we are revisiting a play that has been periodically appearing on our Extended Watchlists since this summer. Following a July 15th alert, we would see KNDI dip as low as 4.41 (07/23). We continued to monitor the stock through to September, as it went on to hit a high of 9.20 (10/26), marking an increase of 109% in roughly three month’s time. However, our adventures with KNDI had only just begun.

By early November, it had settled back to a low of 6.15, and it hasn’t looked back since. Moderate gains gave way to full-on breakout mode on Friday as the stock rocketed to a high of 10.4784, marking a gain of 70% off of its most recent low, and a 138% rise from our original alert low of 4.41. This huge move came just a few days after the following announcement:

This is definitely a story that we will continue to follow in the New Year, as the company expects to increase its delivery of electric vehicles. CEO Hu Xiaoming recently stated: “In 2014, we expect our EV business may surpass our legacy go-cart business and become a major revenue generator for the company,”

More information : http://www.kandivehicle.com

Peregrine Pharmaceuticals, Inc. PPHM

PPHM is an old-time favorite of ours that we wanted to call attention to this morning, as the stock is undergoing some notable pre-market trading action. From lows (1.25) following our most recent alert on PPHM is gapping up significantly, currently trading in the high 1.40’s on a PR fresh out this morning. We’re very interested to see how far the current trend will carry, so keep an eye peeled on PPHM.


Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

Company Launches www.SunriseTrial.com to Assist Patients and Physicians

TUSTIN, CA, Dec 30, 2013 (Marketwired via COMTEX) — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced the opening to enrollment of its SUNRISE trial at leading oncology centers in the United States. SUNRISE is a pivotal Phase III clinical trial comparing the company’s investigational immunotherapy bavituximab plus the chemotherapy docetaxel against placebo plus the chemotherapy docetaxel in patients with second-line non-small cell lung cancer (NSCLC). This trial will enroll approximately 600patients from more than 100 medical centers worldwide. >> FULL PR

Extended Watchlist:
AMMX, PROW, BIOL, CYTR, AVL(Coming off double-bottom)